Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962150 | 0.69 | MAPT (0.48) | KMT2AMAPTMAPK1CYP2C19CYP19A1 | |
| SCHEMBL8996485 | 0.67 | EPHX2 (0.38) | KMT2AMAPTMAPK1CYP2C19MEN1 | |
| SCHEMBL6230510 | 0.66 | KMT2A (0.38) | KMT2AMAPTMAPK1CYP2C19MEN1 | |
| SCHEMBL5423530 | 0.65 | P2RX7 (0.41) | KMT2ACYP2C19MEN1ALDH1A1 | |
| SCHEMBL12191694 | 0.65 | P2RX7 (0.41) | KMT2ACYP2C19MEN1ALDH1A1 | |
| SCHEMBL32688678 | 0.65 | P2RX7 (0.41) | KMT2ACYP2C19MEN1ALDH1A1 | |
| SCHEMBL76783 | 0.65 | P2RX7 (0.41) | KMT2ACYP2C19MEN1ALDH1A1 | |
| SCHEMBL10388136 | 0.64 | KDM4E (0.34) | CYP2C19EPHX2LMNA | |
| SCHEMBL5318552 | 0.64 | CYP2D6 (0.33) | CYP2C19EPHX2 | |
| SCHEMBL7714730 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753127-B2 | USING MIXTURE OF NORBORNENE POLYMER, ACID GENERATOR AND SOLVENT; PREBAKING, EXPOSURE TO RADIATION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2004-06-22 | — | — | US | disclosed |
| US-20030118933-A1 | Norbornene-based copolymer for photoresist, preparation method thereof, and photoresist composition comprising the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118933-A1 | Norbornene-based copolymer for photoresist, preparation method thereof, and photoresist composition comprising the same | ARF1, PTK2, DNAJA1 | KMT2A 2531/4885MAPT 2384/4885MAPK1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.